Literature DB >> 16344300

Liver transplantation for hepatitis C virus related liver disease.

I Gee1, G Alexander.   

Abstract

Liver transplantation is a useful treatment for end stage liver disease of all aetiologies but recurrent disease presents an ongoing challenge, particularly for hepatitis C virus (HCV) where recurrence is almost universal. Immunosuppression is needed for all patients after transplantation and should be tailored to the individual patient, with particular problems being noted for those with HCV. The longer term effects of immunosuppression, particularly renal failure and the adverse effects of certain treatments on the liver graft, have become more important as survival improves and results are studied for longer periods after transplantation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16344300      PMCID: PMC1743404          DOI: 10.1136/pgmj.2005.034082

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  72 in total

1.  Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group.

Authors:  C G Groth; L Bäckman; J M Morales; R Calne; H Kreis; P Lang; J L Touraine; K Claesson; J M Campistol; D Durand; L Wramner; C Brattström; B Charpentier
Journal:  Transplantation       Date:  1999-04-15       Impact factor: 4.939

2.  Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens.

Authors:  G V Papatheodoridis; S G Barton; D Andrew; G Clewley; S Davies; A P Dhillon; G Dusheiko; B Davidson; K Rolles; A K Burroughs
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

3.  Sirolimus: a potent new immunosuppressant for liver transplantation.

Authors:  C J Watson; P J Friend; N V Jamieson; T W Frick; G Alexander; A E Gimson; R Calne
Journal:  Transplantation       Date:  1999-02-27       Impact factor: 4.939

4.  Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.

Authors:  J Ahmad; S F Dodson; A J Demetris; J J Fung; A O Shakil
Journal:  Liver Transpl       Date:  2001-10       Impact factor: 5.799

5.  European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group.

Authors:  C Féray; L Caccamo; G J Alexander; B Ducot; J Gugenheim; T Casanovas; C Loinaz; M Gigou; P Burra; L Barkholt; R Esteban; T Bizollon; J Lerut; A Minello-Franza; P H Bernard; K Nachbaur; D Botta-Fridlund; H Bismuth; S W Schalm; D Samuel
Journal:  Gastroenterology       Date:  1999-09       Impact factor: 22.682

6.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

7.  Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.

Authors:  Ulf P Neumann; Thomas Berg; Marcus Bahra; Daniel Seehofer; Jan M Langrehr; Ruth Neuhaus; Cornelia Radke; Peter Neuhaus
Journal:  J Hepatol       Date:  2004-11       Impact factor: 25.083

8.  Donor age influences 10-year liver graft histology independently of hepatitis C virus infection.

Authors:  Kinan Rifai; Mylène Sebagh; Vincent Karam; Faouzi Saliba; Daniel Azoulay; René Adam; Denis Castaing; Henri Bismuth; Michel Reynès; Didier Samuel; Cyrille Féray
Journal:  J Hepatol       Date:  2004-09       Impact factor: 25.083

9.  A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation.

Authors:  R A Fisher; J M Ham; A Marcos; M L Shiffman; V A Luketic; P M Kimball; A J Sanyal; L Wolfe; A Chodorov; M P Posner
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

10.  Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial.

Authors:  Paul Martin; Ronald W Busuttil; Robert M Goldstein; Jeffrey S Crippin; Goran B Klintmalm; William E Fitzsimmons; Carol Uleman
Journal:  Liver Transpl       Date:  2004-10       Impact factor: 5.799

View more
  1 in total

1.  The current economic burden of cirrhosis.

Authors:  Guy W Neff; Christopher W Duncan; Eugene R Schiff
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.